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Introduction
Identification of axillary metastases in early stage newly diagnosed breast cancer is important for staging disease and planning treatment, but current techniques are associated with a number of adverse events. Approximately 40% of women who present with early stage breast cancer also have axillary metastases. The number of metastases present determines the stage of the disease, contributes to the overall prognosis and helps in the planning of adjuvant treatment. In the UK, women usually follow the diagnostic pathway described in the National Institute for Health and Clinical Excellence (NICE) guidelines(1) (Figure 1 ). If women have a negative ultrasound or ultrasound-guided biopsy of the axilla, they proceed to sentinel lymph node biopsy. Sentinel lymph node biopsy (SLNB) is the excision of the first nodes to receive lymph from the breast (the sentinel nodes). Once removed, the lymph nodes are subject to histological analysis to determine the presence of metastases. If SLNB or the ultrasound-guided biopsy are positive, women proceed to axillary lymph node dissection (ALND), where all lymph nodes are removed to reduce the risk of uncontrolled axillary disease.
SLNB is a highly accurate method of identifying axillary metastases, and whilst it involves the removal of fewer lymph nodes than ALND, it is still associated with both short and long term adverse events. It is estimated that lymphoedema occurs in 21%(2-4) of patients who undergo ALND and 7%(5) of patients who undergo SLNB. Other adverse events include surgical complications such as risk of infection, seroma, insertion of surgical drains and sensitivity to the dyes used in SLNB. Noninvasive alternatives to these diagnostic tests could reduce the incidence of adverse events in women undergoing staging procedures. Any such technique would need to demonstrate acceptable sensitivity to avoid missing metastatic nodes and acceptable specificity to avoid false positive diagnoses, as well as acceptable levels of adverse events.
Magnetic resonance imaging (MRI) is a non-ionising, minimally-invasive in-vivo imaging technique.
Unlike x-ray computerised tomography (CT), which uses the attenuation of ionising radiation as the basis of image contrast, standard MRI relies on the magnetic resonance characteristics of hydrogen nuclei (predominantly associated with water and fat) within the body. The technique utilises how these nuclei respond when placed in a magnetic field and are 'excited' by radio-waves during the application or switching of magnetic field gradients. The resultant signal is used to build up a set of images in 2 or 3 dimensions and, of particular importance, the contrast between different soft-tissues and pathologies can be highly informative, depending on many factors such as the hydrogen nuclei's chemical environment. Of importance to axilla imaging, MRI can thus provide information about the size and morphology of lymph nodes. The administration of intravenous contrast media can give M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT additional information. The presence of exogenous paramagnetic contrast media perturbs the magnetic field at localities where the media collects, which leads to alterations of local image contrast. This can increase lesion conspicuity (where the media collects) and provide additional information regarding the nature of pathological tissue based on the pattern of uptake. Such information can aid the judgement of whether a node is metastatic or not. As well as MRI of hydrogen nuclei attached to water and fat, the technique of proton MR spectroscopy ( 1 H-MRS) can provide information regarding other molecules, the chemical status of which may be relevant to the presence of pathology. To consider MR imaging and spectroscopy as an alternative to SLNB, its sensitivity and specificity must be estimated. We have conducted a systematic review and meta-analysis to evaluate the diagnostic accuracy and adverse events associated with MRI for assessment of axillary metastases in early stage newly diagnosed breast cancer patients.
[ Figure 1 .]
Methods
Search strategy
The systematic review followed the principles recommended in the Preferred Reporting Items for Data extraction and quality assessment Data was extracted from included studies by one reviewer and checked by a second. Studies were quality assessed by two reviewers using the QUality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. (12) In accordance with the guidelines for using QUADAS, two items from the published checklist were omitted as they were not relevant to this review (partial verification bias, incorporation bias). The "description of selection criteria" item was also omitted as this was covered by the "patient spectrum" item, where only studies which recruited early-stage newly-diagnosed patients in a prospective, consecutive manner scored positively. The remaining ten items were used to assess study quality.
Data synthesis
A pooled analysis of results was undertaken where study homogeneity allowed. As sensitivity and specificity are inversely linked, a bivariate random effects method was employed, using Stata (copyright StataCorp). This approach assumes a bivariate normal distribution for the logits of sensitivity and specificity, which allows the correlation between them to be accounted for in the metaregression model; covariates may be used to adjust the (marginal) logits of both sensitivity and specificity.(13;14) Where significant heterogeneity was observed, the random effects method was used in order to account for variation both within and between studies. To explore possible sources of bias, all study quality variables were added as covariates in univariate regression models for sensitivity and specificity to test whether any variables had a significant effect (p < 0.10) on M A N U S C R I P T
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sensitivity or specificity. Review Manager 5 (copyright Cochrane Collaboration) (15)was used to generate graphical representations.
Results
Number and characteristics of included studies
Searches identified 658 unique titles for the broader review relating to imaging of the axilla. The full text of 138 titles were obtained and examined for inclusion in the broad review. Of these, nine titles (16) (17) (18) (19) (20) (21) (22) (23) (24) representing nine studies met the inclusion criteria for this review, and were included. Figure 3 ). Several studies used more than one set of criteria for scoring a node as positive, such as size, morphology, contrast uptake or combinations of these. When pooling the data, results for the criteria that gave the best estimates of diagnostic accuracy per study were used. The pooled estimates of sensitivity and specificity were 90%
(95% confidence interval (CI) 78% to 96%) and 90% (95% CI 75% to 96%) respectively (Table 2) . Table 2 .]
When each MRI modality is considered separately and the estimates of sensitivity and specificity are pooled, USPIO-enhanced MRI gives the highest estimates with a pooled sensitivity of 98% and specificity of 96% (Table 2) . These figures are similar to published estimates of sensitivity and specificity of SLNB (sensitivity of approximately 93-95%, and specificity of 100%, (25;26) )when compared to ALND and are therefore clinically promising. However, it should be noted that the number of patients is small at 93. Gadolinium-enhanced MRI gave somewhat poorer estimates of 88% and 73% respectively (Table 2) , whilst MR spectroscopy estimates are based on one study only, and had sensitivity 65% and specificity 100%.
Subgroup analyses: criteria for positivity
As criteria for positivity varied within and across studies of USPIO enhanced and gadoliniumenhanced MRI, subgroup analyses were performed to assess the effects of these criteria on sensitivity and specificity. Within this analysis, some studies appear more than once. The exact combinations of criteria were often not consistent across studies and the methods of interpreting contrast uptake patterns varied within and between studies.
The most promising diagnostic accuracy in subgroup analyses comes from a pooling of four studies which used USPIO uptake pattern as a criterion for positivity ( Table 2 ). The studies which assessed gadolinium-enhanced MRI used different combinations of criteria for positivity, including uptake pattern, dynamic signal intensity, size, morphology and washout pattern ( Table 2 ). These yielded pairs of estimates lower than those for USPIO-enhanced MRI. Size and morphological criteria for positivity were also considered across the two MRI modalities, though these analyses were mostly based on one study in each category, and none yielded estimates superior to the uptake pattern of USPIO-enhanced MRI.
Sensitivity analyses
Analyses were attempted to assess the effects of study characteristics and study quality on estimates of sensitivity and specificity. Analyses of the effects of size and number of axillary metastases, clinical nodal status, T-stage and reference standard used were not possible due to lack of data or lack M A N U S C R I P T
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of variation in data between studies. Studies in which all analysed patients were early-stage newlydiagnosed and did not have a diagnosis of DCIS had a trend towards a higher sensitivity, and a significantly lower specificity, than studies in which not all patients were early-stage, newlydiagnosed and non-DCIS; however, there was wide variation in results between studies. There was no clear correlation between prevalence of axillary metastases within the study and estimates of sensitivity and specificity. There was also no clear correlation between any of the quality assessment items and estimates of diagnostic accuracy, but this analysis is limited by a lack of variation in quality assessment scores between studies.
Withdrawal rates and adverse events
Four studies reported that between 3% and 18% of patients withdrew. Reasons for withdrawal included no ALND, inadequate MRI data, and claustrophobia or poor health. No serious adverse effects were reported in any of the MRI studies. Mild-to-moderate adverse effects included mild rash following USPIO administration (recovered without treatment or following antihistamine treatment) and inability to complete the MRI scan due to claustrophobia or back pain as a result of holding the same position for some time. In addition, many of the studies excluded patients with contraindications
to MRI, such as strong allergic disposition, allergy to contrast agents, or liver dysfunction.
Discussion
Overall pooled estimates of sensitivity and specificity for MRI were 90% and 90% respectively, with USPIO-enhanced MRI giving the highest overall diagnostic accuracy with sensitivity of 98% and specificity of 96%. Gadolinium-enhanced MRI gave sensitivity of 88% and specificity of 73% and MR spectroscopy gave a sensitivity of 65% and specificity of 100%. Confidence intervals were wide, and there was considerable variation in the criteria used to class a node as positive.
This study uses a bivariate random effects method of meta-analysis to pool estimates of sensitivity and specificity, which takes into account the inverse relationship between the two values. We have also made a thorough review of the literature to April 2009, and the brief update search performed in MEDLINE in January 2011 indicates that no eligible studies have been published subsequently.
However, the study is limited by the small amount of available data, both in terms of numbers of participants and numbers of studies.
SLNB is reported to have a sensitivity of approximately 93-95%, and a specificity of 100%. (25;26) Replacing SLNB at a population level with MRI, based on the overall pooled estimates within this M A N U S C R I P T
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review (pooled sensitivity 90%, specificity 90%), would result in an increase in missed metastases as MRI has a lower sensitivity than SLNB, leading to more false negative cases. It would result in an increase in unnecessary ALND procedures, as MRI has lower specificity than SLNB, leading to more false positive cases. It would also mean a large number of women would not undergo SLNB and would therefore avoid the risk of adverse events associated with these procedures. However, the associated increase in women with false negative results who would therefore be put at greater risk of cancer recurrence may not be acceptable despite the reduction in adverse events.
Subgroup analyses indicated, however, that USPIO-enhanced MRI had superior sensitivity (98%), but inferior specificity (96%) to SLNB. In addition, subgroup analyses indicate that the criteria used to classify a node as positive may affect diagnostic accuracy, though wide confidence intervals preclude firm conclusions. Whilst these results come from a small number of patients and the criteria for positivity varied between the studies that have been pooled, they are promising and fall within the ranges of sensitivity reported for SLNB. Further technological development, especially of USPIOenhanced MRI, would seem warranted, and research to identify the optimal criteria for classing a node as positive may lead to improvements in diagnostic accuracy independent of technological advances.
Given current estimates of diagnostic accuracy, an alternative strategy, where MRI is added to the current pathway before ALND/SLNB, could be considered. This way, women at greatest risk MRI criteria USPIO uptake USPIO uptake USPIO uptake USPIO uptake USPIO + >10mm + round *Where studies report results using more than one set of criteria for positivity, these analyses use data corresponding to the criteria with the highest reported estimates of diagnostic accuracy per study. Gd = Gadolinium M A N U S C R I P T
